Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06873204 · ClinicalTrials.gov registry record · NA
Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults
A NA study, sponsored by Purdue University.
- Not yet
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT06873204 is a NA study that has not yet begun recruiting, run by Purdue University. The registered enrollment target is 25 participants.
The verdict
NCT06873204, a NA study, has not yet begun recruiting, sponsored by Purdue University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The importance of the gut microbiota for general health has been recently elucidated, but little is known about the impact of different types of nutrients on the gut microbiota. The soluble fiber in cereal by-products, arabinoxylan (AX), is known to be beneficial for generally promoting gut health. However, it is unclear whether consuming rice bran (RB), the source of AX, is equally helpful or better than consuming the extracted form of AX. This study aims to reveal the potential benefit of insoluble cereal bran fiber ingredients by comparing the effect of soluble arabinoxylan fiber alone and the mostly insoluble rice bran fiber, containing arabinoxylan, on intestinal health and gut microbiota. A placebo (maltodextrin) will be used as a control, with no significant changes expected in this group for the evaluated outcomes. Participants will: * Consume two different fiber supplements (soluble arabinoxylan or stabilized rice bran) as well as a placebo (maltodextrin) for 3 weeks each, separated by a 2-week washout period. * Provide blood and stool samples at six different time points. * Complete a food and gastrointestinal symptom diary during the intervention periods.
Interventions
- DIETARY_SUPPLEMENT Maltodextrin (Placebo)
- DIETARY_SUPPLEMENT Soluble Arabinoxylan
- DIETARY_SUPPLEMENT Rice Bran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-07 |
| Est. Completion | 2025-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06873204
The ClinicalTrials.gov registry entry for NCT06873204 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue University, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Maltodextrin (Placebo) is the first listed.
NCT06873204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06873204 about?
NCT06873204 is a clinical study titled "Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults". The importance of the gut microbiota for general health has been recently elucidated, but little is known about the impact of different types of nutrients on the gut microbiota. The soluble fiber in cereal by-products, arabinoxylan (AX), is known to be beneficial for generally promoting gut health. ...
What is the current status of trial NCT06873204?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2025-07. Estimated completion is 2025-10.
What interventions are being tested in trial NCT06873204?
The interventions under investigation include: Maltodextrin (Placebo) (DIETARY_SUPPLEMENT), Soluble Arabinoxylan (DIETARY_SUPPLEMENT), Rice Bran (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06873204?
This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.